
Trogenix doses first patient in Phase I/II trial of TGX-007 gene therapy for glioblastoma.
Trogenix has dosed the first patient in its Phase I/II ADePT trial testing TGX-007, a dual-payload gene therapy for glioblastoma, at sites in the UK and US. TGX-007 uses a proprietary Synthetic Super-Enhancer platform to selectively kill tumor cells ...


